MSD is reported to have been negotiating with Swiss biotech MoonLake Immunotherapeutics over a takeover deal – estimated to be worth more than $3 billion – according to media reports. The Financial ...
MSD is expecting to see an additional $200 million layered onto its costs this year as a result of President Trump's tariffs – even before a possible pharma-specific levy is announced. The US pharma ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the ...
We independently review everything we recommend. We may get paid to link out to retailer sites, and when you buy through our links, we may earn a commission. Learn more› If you need a family computer ...
To get access to ad-free episodes, exclusive podcasts, unlimited briefings, stories, and transcripts, and other valuable bonus features sign up today. A new executive order targets states’ AI ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback